[Nature sub-issue] "Armed CAR-T cells" to better fight cancer and improve the possibility of successful treatment of solid tumors!

This article is original for Translational Medicine.
Please indicate the source when reprinting.
Author: Ashley Introduction: CAR-T cells are effective against hematological malignancies
.

However, in solid tumors, local immunosuppression and heterogeneous expression of CAR-targeted antigens hinder its efficacy
.

Recent studies have armed CAR-T cells to better fight cancer by introducing a gene encoding the immune-stimulating protein NAP (neutrophil-activating protein) from Helicobacter pylori, increasing the likelihood of successful treatment of solid tumors
.

Immunotherapy is increasingly becoming a successful treatment for cancer
.

Researchers at Uppsala University have now developed armed CAR-T cells that strengthen the immune defense against cancer, which could increase the likelihood of successful treatment of solid tumors
.

The study, "CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers," has been published in the journal Nature Biomedical Engineering
.

https:// There is an increasing use of immunotherapy to treat cancer, and genetically modified immune cells called CAR-T cells are effective in treating blood cancers
.

Unfortunately, their efficiency in solid tumors is compromised due to local immunosuppression of the tumor
.

To avoid this problem, the Uppsala researchers armed CAR-T cells by introducing a gene encoding the immune-stimulating protein NAP (neutrophil-activating protein) from Helicobacter pylori
.

When NAP is released from CAR-T cells, this creates a pro-inflammatory environment that directly counteracts the immunosuppressive microenvironment in solid tumors and enhances CAR-T cell function
.

"We believe that this new technology of arming CAR-T cells has the potential to revolutionize CAR-T cell therapy
.

NAP secreted from armed CAR-T cells can reverse tumors from immunologically 'cold' to 'hot'
In
addition, NAP can also recruit other types of immune cells that can attack tumor cells that CAR-T cells cannot recognize," said researcher Di Yu
.

To study the role of CAR(NAP)-T cells, the researchers treated mice with different types of tumors and found that tumor growth was reduced
.

Survival was also increased compared to using NAP-free CAR-T cells
.

The researchers also studied human CAR (NAP)-T cells in in vitro experiments and found that they had better immune-stimulating capacity than conventional human CAR-T cells
.

"We have a strong tradition of CAR-T cell therapy in cancer at Uppsala, where Gunilla Enblad and Angelica Loskog treated the first patients in Europe as early as 2014.

Uppsala
University Hospital conducted two academic trials with a total of 39 patients
.

Based on the strong results in our Nature Biomedical Engineering paper, we are now planning a clinical trial with our novel armed CAR-T cells
.

We hope to treat the first patient by the end of this year," Prof.
Magnus Essand say
.

Reference: https://medicalxpress.
com/news/2022-04-armed-car-t-cells-cancer.
html Note: This article aims to introduce the progress of medical research and cannot be used as a reference for treatment plans
.

For health guidance, please go to a regular hospital for treatment
.

Recommendation·Event Click on the text or scan the QR code to view the details.
April 8th, 15:00-16:30 MGI C4 - Cell for All Online Seminar Series "Nature Author Face-to-face" Scanning and Booking Live April 13th 19:00-21:00 Online "Drug Precision" Phase 4: Innovative Drug R&D and Research and Development Salon Scanning Appointment Live Streaming April 14th 15:00-16:20 Online Targets Based on Real-time Live Cell Imaging Analysis Live broadcast of scan reservation for tumor treatment plan April 15th 14:00-15:00 Online Mozhuo MobiNova-100 high-throughput single-cell bank building system press conference Scanning appointment live broadcast April 20th 14:00-16:00 How to improve the research and development efficiency of new macromolecular drugs from basic experiments